Adamis’ shares nosedive as sole clinical-stage asset flunks COVID-19 trial September 21, 2022 5:44 am https://www.fiercebiotech.com/biotech/adamis-shares-nosedise-sole-unapproved-asset-flunks-covid-trial
What They Said – FDA Press Releases Mid-2021 Leave a Comment / Biotechnology, FDA, Medical Device, Regulatory Affairs / By MedicalInnovationExchange It has been a regular feature of the blog to give a read on what…
Crisis Communications and FDA Leave a Comment / Biotechnology, FDA, Medical Device, Regulatory Affairs / By MedicalInnovationExchange In the face of a crisis situation, it is a given that the clarity and…
AdComms – Is FDA Getting Less Advice? Leave a Comment / Biotechnology, FDA, Medical Device, Regulatory Affairs / By MedicalInnovationExchange As more drugs are being approved, is FDA getting less advice than in the past?…
FDA Authorizes Third Dose – Some Implications Leave a Comment / Biotechnology, FDA, Medical Device, Regulatory Affairs / By MedicalInnovationExchange What does “fully vaccinated” mean today? In the face of the widening spread of the…
How your healthcare business can generate more leads Leave a Comment / Consulting, FDA, Medical Device, MedTech / By MedCity News MedCity News has launched the Knowledge Hub to help you get targeted healthcare leads and…
Medtronic expands recall of MiniMed insulin pumps Leave a Comment / Consulting, FDA, Medical Device, MedTech / By Elise Reuter Medtronic is recalling its MiniMed 670G system after reports of broken retainer rings for insulin…
This startup wants to build a needle-free CGM using nanotechnology Leave a Comment / Consulting, FDA, Medical Device, MedTech / By Elise Reuter Graphwear co-founders Saurabh Radhakrishnan and Rajatesh Gudibande want to make CGMs that use nanotechnology to…
Sepsis: Treating a global health crisis at the point of care Leave a Comment / Consulting, FDA, Medical Device, MedTech / By Avishay Bransky A major global health crisis that we find ourselves facing today is sepsis – the…